A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)
Primary Purpose
Breast Cancer
Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
capecitabine
capecitabine + camrelizumab + apatinib
Sponsored by

About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring stage II-III
Eligibility Criteria
Inclusion Criteria:
- Patient is ≥ 18 years-old at the time of consent to participate this trial
- Stage II - III primary triple negative breast cancer patients(TNBC), TNBC is defined as ER <=1%, PR <=1%;HER2 receptor IHC=1, or IHC=2 and FISH negative.
- positive ctDNA after curative surgery and/or adjuvant chemotherapy
- ECOG 0-2
- If indicated, patient agree to receive adjuvant radiotherapy according to the institutional guidelines
- Patient receives adjuvant chemotherapy according to the NCCN guidelines
- Patient has available tumor tissue from the surgical specimen for next generation sequencing(NCS)
- Patient agrees to give blood samples for ctDNA tests every 3 months in 5 years
Exclusion Criteria:
- Patient has previously received any PD1/PDL1 blockage treatment
- Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial
- Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition)
- Patient participates another interventional clinical trial
- Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 3 years before randomization
- Patient with autoimmune disease preventing the use of camrelizumab
- Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol
Sites / Locations
- Sunyat-sen Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Capecitabine
Capecitabine + Apatinib + Camrelizumab
Arm Description
Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year
Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year
Outcomes
Primary Outcome Measures
Invasive Disease Free Survival(IDFS)
Invasive Disease-Free Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
Secondary Outcome Measures
Distant disease-free survival(DDFS)
Distant Disease-Free Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
Overall Survival
Overall Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
Brain metastasis rate
Brain metastasis rate for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
The rate of adverse effects(AEs)
AEs related to apatinib and/or camrelizumab
Full Information
NCT ID
NCT04803539
First Posted
March 16, 2021
Last Updated
February 16, 2023
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators
Jiangsu HengRui Medicine Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04803539
Brief Title
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
Acronym
Artemis
Official Title
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2021 (Actual)
Primary Completion Date
September 1, 2028 (Anticipated)
Study Completion Date
September 1, 2033 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators
Jiangsu HengRui Medicine Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Circulating tumor DNA (ctDNA) has been demonstrated to be an effective prognostic marker in breast cancer. Various studies have shown that early TNBC breast cancer patients with positive ctDNA have high risk of cancer recurrence and worse prognosis. This study aimed to identify TNBC patients with positive ctDNA and initiate boost therapy in these high risk patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
stage II-III
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
260 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Capecitabine
Arm Type
Active Comparator
Arm Description
Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year
Arm Title
Capecitabine + Apatinib + Camrelizumab
Arm Type
Experimental
Arm Description
Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year
Intervention Type
Drug
Intervention Name(s)
capecitabine
Intervention Description
capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
Intervention Type
Drug
Intervention Name(s)
capecitabine + camrelizumab + apatinib
Intervention Description
Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
Primary Outcome Measure Information:
Title
Invasive Disease Free Survival(IDFS)
Description
Invasive Disease-Free Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
Time Frame
60 months
Secondary Outcome Measure Information:
Title
Distant disease-free survival(DDFS)
Description
Distant Disease-Free Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
Time Frame
60 months
Title
Overall Survival
Description
Overall Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
Time Frame
60 months
Title
Brain metastasis rate
Description
Brain metastasis rate for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria
Time Frame
60 months
Title
The rate of adverse effects(AEs)
Description
AEs related to apatinib and/or camrelizumab
Time Frame
60 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is ≥ 18 years-old at the time of consent to participate this trial
Stage II - III primary triple negative breast cancer patients(TNBC), TNBC is defined as ER <=1%, PR <=1%;HER2 receptor IHC=1, or IHC=2 and FISH negative.
positive ctDNA after curative surgery and/or adjuvant chemotherapy
ECOG 0-2
If indicated, patient agree to receive adjuvant radiotherapy according to the institutional guidelines
Patient receives adjuvant chemotherapy according to the NCCN guidelines
Patient has available tumor tissue from the surgical specimen for next generation sequencing(NCS)
Patient agrees to give blood samples for ctDNA tests every 3 months in 5 years
Exclusion Criteria:
Patient has previously received any PD1/PDL1 blockage treatment
Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial
Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition)
Patient participates another interventional clinical trial
Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 3 years before randomization
Patient with autoimmune disease preventing the use of camrelizumab
Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shunying Li, MD
Phone
86-020-34071156
Email
lishunying@foxmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Qiang Liu, PhD
Phone
86-020-34071157
Email
victorlq@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Qiang Liu, PhD
Organizational Affiliation
Sunyat-sen Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sunyat-sen Memorial Hospital
City
Guandong
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
shunying Li
Phone
+86-15915939702
Email
lishunying@foxmail.com
12. IPD Sharing Statement
Learn more about this trial
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
We'll reach out to this number within 24 hrs